APOE and Alzheimer disease: Because homozygous APOE ɛ4 carriers are particularly relevant to AD pathology, we compared the baseline ALZpath p‐tau217, p‐tau217+ Janssen, and p‐tau181 levels between heterozygous and homozygous APOE ɛ4 carriers.